The Dual mTORC1 and mTORC2 Inhibitor PP242 Shows Strong Antitumor Activity in a Pheochromocytoma PC12 Cell Tumor Model
Authors:
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Circadian Regulation of mTOR by the Ubiquitin Pathway in Renal Cell CarcinomaCancer Research, 2014
- The antiproliferative effects of ouabain and everolimus on adrenocortical tumor cellsEndocrine Journal, 2014
- Current and Future Treatments for Malignant Pheochromocytoma and Sympathetic ParagangliomaCurrent Oncology Reports, 2013
- Molecular and Therapeutic Advances in the Diagnosis and Management of Malignant Pheochromocytomas and ParagangliomasThe Oncologist, 2013
- Rationale for Anti-angiogenic Therapy in Pheochromocytoma and ParagangliomaEndocrine Pathology, 2011
- Rapamycin passes the torch: a new generation of mTOR inhibitorsNature Reviews Drug Discovery, 2011
- EverolimusClinical Cancer Research, 2010
- Rapamycin inhibits mTORC1, but not completelyAutophagy, 2009
- Novel and Evolving Therapies in the Treatment of Malignant Phaeochromocytoma: Experience with the mTOR Inhibitor Everolimus (RAD001)Hormone and Metabolic Research, 2009
- The Pharmacology of mTOR InhibitionScience Signaling, 2009